Right now, the loudest signal is about a plan at the University of Miami to study ibogaine, a plant medicine some veterans say pulled them out of deep trauma and addiction. The plan has drawn heavy political and media interest. But almost every serious scientist looking at it keeps raising the same warning: ibogaine can throw off the heart's rhythm in a dangerous way. Our swarm gives strong odds — around 70% — that when the FDA, the U.S. agency that approves medicines, responds to this study plan, it will demand heart monitoring as a condition before anyone is dosed. That isn't politics getting in the way. That is doctors doing their job.
In the markets, one company, Compass Pathways (ticker CMPS), rose 6.3% while others slipped. A jump in one company while its neighbors fall usually means someone knows something not yet public. We expect Compass to reveal a specific reason — a trial date, new money, or a partnership — in an official statement before the end of September. Meanwhile, quieter ketamine studies for trauma and depression keep moving forward, because ketamine isn't stuck in the government's most restricted drug category the way the others are.
Beneath the surface, a clear pattern is forming. The flashy headlines — the political endorsements, the big announcements — run far ahead of the actual proof. Getting permission to plan a study is paperwork. Actually treating patients is months away, and there's a second hurdle almost nobody talks about: researchers still need a separate special license from the DEA, the drug-enforcement agency, just to handle ibogaine legally. So expect a gap. Loud coverage on one side, slow real progress on the other. The highest path here isn't the one that moves fastest. It's the one that takes the heart-safety question seriously now, so the medicine that reaches veterans is one that helps them without a hidden cost.
For the real people inside this story — the veterans who've tried everything and still wake up at 3 a.m. with their war still running in their heads — this is the tension they live with. They've heard ibogaine gave someone their life back. They want that door open yesterday. And the honest, loving answer is: the door is opening, but it has to open in a way that doesn't trade one danger for another. The heart monitoring isn't a delay standing between them and hope. It is the thing that makes the hope real and lasting. The people doing this carefully are not their obstacle. They are on their side.
OOTW doesn't sell products. It delivers transmissions — a daily reminder that the intelligence which created us is still creating, still calling us forward.
The intelligence that created you is still creating.
72%
Heart risk will dominate expert debate on ibogaine drug application
When scientists and officials talk about the University of Miami's application to study ibogaine (a powerful plant-based psychedelic) in clinical trials, the conversation will center on one thing: it can cause dangerous, potentially fatal heart rhythm problems. This matters because it's the main hurdle between ibogaine and patients who might benefit from it — especially veterans with treatment-resistant PTSD.
→ Heart rhythm problems are ibogaine's biggest scientific obstacle, and every expert reviewing the University of Miami's trial application will say so front and center.
Resolves: 2026-10-19 · Global
RESEARCH
the precise call ▾
Cardiac safety (hERG/QT/torsades) will be the dominant scientific caveat cited in expert and official commentary on the UMiami ibogaine IND over the next 8 weeks.. It's the honest pharmacological answer. Every serious reviewer converges here regardless of politics — the ion-channel data isn't debatable.
70%
US drug regulator will demand heart monitoring in ibogaine trial review
The FDA (the US drug regulator) is widely expected to respond to the University of Miami's ibogaine study application by requiring strict heart monitoring for every participant — think continuous heart-rhythm tracking throughout the experience. This is because ibogaine is known to interfere with the heart's electrical system in ways that can cause sudden, life-threatening irregular heartbeats. The FDA won't approve any human dosing without guardrails around that risk.
→ Before any ibogaine trial at the University of Miami can start dosing people, the FDA will almost certainly require continuous heart monitoring — and that requirement will arrive in writing before mid-November 2026.
Resolves: 2026-11-15 · USA
REGULATORY
the precise call ▾
FDA response to the UMiami ibogaine IND will include an explicit cardiac-monitoring requirement (QT/telemetry) in any clinical-hold or clinical-comment communication before Nov 15, 2026.. Ibogaine's torsadogenic risk is well-documented; no reviewer signs off without cardiac guardrails. This is standard division practice, politics aside.
70%
No standalone psychedelic law will get a full House vote by year-end 2026
Any bill in the US House of Representatives that focuses specifically on expanding access to psychedelics as medicine won't make it to a full floor vote before the end of 2026. Instead, any progress on psychedelics in federal law will be tucked inside larger must-pass bills — like the defense budget (called the NDAA, the National Defense Authorization Act) or spending bills. Standalone bills on controversial topics rarely get scheduled in election-adjacent years because lawmakers don't want to be on the record without political cover.
→ Any federal psychedelic legislation that actually moves in 2026 will be hidden inside a bigger bill — no standalone law is getting a full House vote this year.
Resolves: 2026-12-31 · Global
LEGISLATION
the precise call ▾
No standalone psychedelic access bill will receive a House floor vote before year-end 2026; all action stays inside NDAA/appropriations.. Election-year caution keeps members from standalone votes. Vehicles with cover survive; exposed bills don't get scheduled.
68%
Ibogaine media hype will far outrun actual trial progress through late 2026
There will be a huge wave of news coverage about the University of Miami's ibogaine application, but the actual clinical trial — where real patients get treated and data gets collected — won't meaningfully begin before November 2026. The application itself (called an IND, or Investigational New Drug application) is just paperwork giving researchers permission to try. Political involvement, including interest from Trump-aligned figures, will fuel coverage that makes things sound further along than they are.
→ Ibogaine will get massive news coverage through November 2026, but the actual trial treating real patients will barely have started — the hype will run way ahead of the reality.
Resolves: 2026-11-30 · Global
MEDIA
the precise call ▾
UMiami ibogaine IND coverage will outpace actual enrolling-trial milestones by a wide margin through November 2026.. INDs are paperwork; enrollment is months out. Political theater and Trump's involvement guarantee coverage volume dwarfs clinical substance.
67%
Politics and press will dominate ibogaine news while real science lags
Multiple independent perspectives — from journalists, scientists, and policy experts — agree that the story of ibogaine in late 2026 will be driven far more by politics and media attention than by actual clinical results. The University of Miami's application will generate enormous coverage, especially given political figures' involvement, but meaningful trial milestones — like enrolling patients and generating data — will come much later if at all this year.
→ Politics and press attention will dominate the ibogaine story in 2026, while the actual science of treating patients moves much more slowly and quietly.
Resolves: 2026-11-22 · Global
MEDIA
the precise call ▾
UMiami ibogaine IND generates far more political/media coverage than actual enrolling-trial milestones through November 2026.. Consensus of 3 agents: journalist, dea_officer, neuroscientist. 1 dissenting.